WuXi Biologics expects 16% revenue growth, 54% profit jump

WuXi Biologics expects 16% revenue growth and gross profit margin expansion of 3.6% year-on-year for the six months ended June 30, 2025.

Profit and profit attributable to equity shareholders are projected to increase by 54% and 56% respectively. Non-IFRS adjusted net profit is expected to rise 11%.